Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Heparan Sulfate Biosynthetic System Is Inhibited in Human Glioma Due to EXT1/2 and HS6ST1/2 Down-Regulation.

Ushakov VS, Tsidulko AY, de La Bourdonnaye G, Kazanskaya GM, Volkov AM, Kiselev RS, Kobozev VV, Kostromskaya DV, Gaytan AS, Krivoshapkin AL, Aidagulova SV, Grigorieva EV.

Int J Mol Sci. 2017 Nov 1;18(11). pii: E2301. doi: 10.3390/ijms18112301.

2.

Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract.

Lee HY, Yeh BW, Chan TC, Yang KF, Li WM, Huang CN, Ke HL, Li CC, Yeh HC, Liang PI, Shiue YL, Wu WJ, Li CF.

Oncotarget. 2017 Jul 18;8(29):47216-47229. doi: 10.18632/oncotarget.17590.

3.

Impact of Sulfatase-2 on cancer progression and prognosis in patients with renal cell carcinoma.

Kumagai S, Ishibashi K, Kataoka M, Oguro T, Kiko Y, Yanagida T, Aikawa K, Kojima Y.

Cancer Sci. 2016 Nov;107(11):1632-1641. doi: 10.1111/cas.13074.

4.

Expression of the extracellular sulfatase SULF2 is associated with squamous cell carcinoma of the head and neck.

Flowers SA, Zhou X, Wu J, Wang Y, Makambi K, Kallakury BV, Singer MS, Rosen SD, Davidson B, Goldman R.

Oncotarget. 2016 Jul 12;7(28):43177-43187. doi: 10.18632/oncotarget.9506.

5.

Involvement of SULF2 in y-irradiation-induced invasion and resistance of cancer cells by inducing IL-6 expression.

Jung CH, Ho JN, Park JK, Kim EM, Hwang SG, Um HD.

Oncotarget. 2016 Mar 29;7(13):16090-103. doi: 10.18632/oncotarget.7449.

6.

SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.

Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H.

PLoS One. 2016 Feb 16;11(2):e0148911. doi: 10.1371/journal.pone.0148911. eCollection 2016.

7.

Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis.

Shire A, Lomberk G, Lai JP, Zou H, Tsuchiya N, Aderca I, Moser CD, Gulaid KH, Oseini A, Hu C, Warsame O, Jenkins RB, Roberts LR.

Med Epigenet. 2015 Jan-Apr;3(1):1-18.

8.

Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.

Meier JC, Haendler B, Seidel H, Groth P, Adams R, Ziegelbauer K, Kreft B, Beckmann G, Sommer A, Kopitz C.

Cancer Med. 2015 Feb;4(2):253-67. doi: 10.1002/cam4.354. Epub 2014 Dec 10.

9.

The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.

Hammond E, Khurana A, Shridhar V, Dredge K.

Front Oncol. 2014 Jul 24;4:195. doi: 10.3389/fonc.2014.00195. eCollection 2014. Review.

10.

CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis.

Shang B, Gao A, Pan Y, Zhang G, Tu J, Zhou Y, Yang P, Cao Z, Wei Q, Ding Y, Zhang J, Zhao Y, Zhou Q.

Cell Death Dis. 2014 Jun 5;5:e1285. doi: 10.1038/cddis.2014.244.

11.

Post-Synthetic Regulation of HS Structure: The Yin and Yang of the Sulfs in Cancer.

Vivès RR, Seffouh A, Lortat-Jacob H.

Front Oncol. 2014 Jan 14;3:331. doi: 10.3389/fonc.2013.00331. eCollection 2014 Jan 14. Review.

12.

The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors.

Szatmári T, Dobra K.

Front Oncol. 2013 Dec 19;3:310. doi: 10.3389/fonc.2013.00310. Review.

13.

The glycome of normal and malignant plasma cells.

Moehler TM, Seckinger A, Hose D, Andrulis M, Moreaux J, Hielscher T, Willhauck-Fleckenstein M, Merling A, Bertsch U, Jauch A, Goldschmidt H, Klein B, Schwartz-Albiez R.

PLoS One. 2013 Dec 26;8(12):e83719. doi: 10.1371/journal.pone.0083719. eCollection 2013.

14.

Heparan sulfate and heparanase as modulators of breast cancer progression.

Gomes AM, Stelling MP, Pavão MS.

Biomed Res Int. 2013;2013:852093. doi: 10.1155/2013/852093. Epub 2013 Jul 31. Review.

15.

Role of heparan sulfatases in ovarian and breast cancer.

Khurana A, Beleford D, He X, Chien J, Shridhar V.

Am J Cancer Res. 2013;3(1):34-45. Epub 2013 Jan 18.

16.

SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study.

Lui NS, van Zante A, Rosen SD, Jablons DM, Lemjabbar-Alaoui H.

BMJ Open. 2012 Nov 23;2(6). pii: e001624. doi: 10.1136/bmjopen-2012-001624. Print 2012.

17.

Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells.

Szatmári T, Mundt F, Heidari-Hamedani G, Zong F, Ferolla E, Alexeyenko A, Hjerpe A, Dobra K.

PLoS One. 2012;7(10):e48091. doi: 10.1371/journal.pone.0048091. Epub 2012 Oct 29.

18.

The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling.

Zheng X, Gai X, Han S, Moser CD, Hu C, Shire AM, Floyd RA, Roberts LR.

Genes Chromosomes Cancer. 2013 Mar;52(3):225-36. doi: 10.1002/gcc.22022. Epub 2012 Oct 29.

19.

Over-expression of human endosulfatase-1 exacerbates cadmium-induced injury to transformed human lung cells in vitro.

Zhang H, Newman DR, Bonner JC, Sannes PL.

Toxicol Appl Pharmacol. 2012 Nov 15;265(1):27-42. doi: 10.1016/j.taap.2012.09.008. Epub 2012 Sep 19.

20.

HSULF-1 inhibits ERK and AKT signaling and decreases cell viability in vitro in human lung epithelial cells.

Zhang H, Newman DR, Sannes PL.

Respir Res. 2012 Aug 8;13:69. doi: 10.1186/1465-9921-13-69.

Supplemental Content

Support Center